Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.


MHRA further measures to minimise risk of ONJ with denosumab and IV bisphosphonates

23rd July 2015

Denosumab 120mg is now contra-indicated in patients with unhealed lesions from dental or oral surgery, this follows a review by MHRA and other EU regulators.

In addition, patient reminder cards are being introduced and should be given to all patients receiving denosumab or IV bisphosphonates to inform them of the risk of osteonecrosis of the jaw (ONJ) and the precautions to take before and during treatment. The reminder cards will be provided by the product licence/marketing authorization holders for the individual products. An example of the content of the reminder cards can be seen for denosumab from the links below.

Prolia (denosumab) reminder card 

Xgeva (denosumab) reminder card 

click here to view